Astrazeneca, intranasal vaccination to stop Covid?

13 January 20213 years ago babelfish

Vaccination with intranasal ChAdOx1 carried out on macaques and hamsters stops the spread of Covid-19. The report of bioRxiv

The ChAdOx1 nCoV-19 vaccine (AZD1222) developed by the University of Oxford, in collaboration with the Italian Irbm and produced by Astrazeneca, now under examination by the EMA, could block the spread of Covid if administered intranasally.

All the details.

THE INTRANASAL EXPERIMENTATION ON MACACHI

As reported by bioRxiv , vaccination with intranasal ChAdOx1, carried out on rhesus macaques affected by the D614G variant of coronavirus 2 (SARS-CoV-2) with severe acute respiratory syndrome in return, decreases the viral spread of the disease.

"Intranasal vaccination of rhesus macaques resulted in a reduction in shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue," explains the scientific article.

STOP TO DIFFUSION ALSO ON HAMSTERS

The solution was also effective in Syrian hamsters. Viral load in swabs from nasally vaccinated hamsters was significantly reduced compared to previous controls and no viral RNA or infectious virus was found in lung tissue, "either in a direct challenge or in a transmission model," he explains. BioRxiv.

THE DIFFERENCES WITH AN INTRAMUSCULAR VACCINATION

The above is good news. Intramuscular vaccination with ChAdOx1 nCoV-19 / AZD1222 protected rhesus macaques from pneumonia and severe disease, but did not reduce the spread of SARS-CoV-2.

INTRANASAL VACCINATION ON HUMANS

The possible implications of intranasal vaccination on humans are still unknown. If this were also confirmed in humans, or if an intranasal use could block the spread of the virus, "it would really be a game changer", comments Roberta Villa, journalist with a degree in medicine and surgery, research fellow for the Ca 'University Foscari of Venice.

If it were confirmed in humans it would really be a game changer https://t.co/aT8lnE4CzC

– Roberta Villa (@RobiVil) January 13, 2021

THE VACCINE

The viral-vectored ChAdOx1 nCoV-19 vaccine uses a modified version of the chimpanzee adenovirus, no longer able to replicate, as a vector to provide instructions for synthesizing the SARS-CoV-2 spike protein. The protein, once produced, therefore, can stimulate the immune response, both antibody and cellular.

EFFECTIVENESS

The drug has shown an overall efficacy of 70.4%, after two doses, in preventing Covid-19 in people between the ages of 18 and 55. Efficacy was 62.1% in participants who received two full doses and 90% in participants who received only half a dose on the first and full dose on the second.

WAITING FOR EMA

The vaccine is being evaluated on the tables of the EMA, the European Medicines Agency, which will have to express itself by January 29th.

This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/astrazeneca-vaccinazione-intranasale-per-fermare-il-covid/ on Wed, 13 Jan 2021 15:34:55 +0000.